📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Novel epigenetic therapies in hematological malignancies: Current status and beyond (2018)

First Author: Gallipoli P

Attributed to: Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.semcancer.2017.07.005

PubMed Identifier: 28782607

Publication URI: http://europepmc.org/abstract/MED/28782607

Type: Journal Article/Review

Parent Publication: Seminars in Cancer Biology

ISSN: 1044-579X